Products for Research Use Only

REV 5901

CAT: 0804-HY-112532-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-112532-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
REV 5901 is a competitive and orally active antagonist of leukotriene receptor, with a Ki of 0.7 μM. REV 5901 is also a 5-lipoxygenase inhibitor. REV 5901 can be used for the research of asthma in which leukotriene release be involved. REV 5901 can be used for the study of colon carcinoma[1][2][3].
CAS Number
101910-24-1
UNSPSC
12352005
Hazard Statement
H315, H319, H335
Target
Leukotriene Receptor; Lipoxygenase
Type
Reference compound
Related Pathways
GPCR/G Protein; Metabolic Enzyme/Protease
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/rev-5901.html
Purity
99.9
Solubility
DMF : 36 mg/mL (ultrasonic; warming)
Smiles
OC(CCCCC)C1=CC=CC(OCC2=NC3=CC=CC=C3C=C2)=C1
Molecular Formula
C22H25NO2
Molecular Weight
335.44
Precautions
H315, H319, H335
References & Citations
[1]Inwegen RGV, et, al. REV 5901: an orally effective peptidoleukotriene antagonist, detailed biochemical/pharmacological profile. J Pharmacol Exp Ther. 1987 Apr;241 (1) :117-24.|[2]Anderson G, et, al. Effects of REV 5901, a 5-lipoxygenase inhibitor and leukotriene antagonist, on pulmonary responses to platelet activating factor in the guinea-pig. Br J Pharmacol. 1988 Aug;94 (4) :1115-22. |[3]Paskaš S, et al. Carborane-Based Analog of Rev-5901 Attenuates Growth of Colon Carcinoma In Vivo. Molecules. 2022 Jul 14;27 (14) :4503.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported